Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,883 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the "polmone toscano group" (POLTO).
Tibaldi C, Ricci S, Russo F, Bernardini I, Galli L, Chioni A, Orlandini C, Grosso AM, Pegna AL, Fabbri A, Innocenti F, Ferrari K, Tognarini L, Conte PF, Falcone A; POLTO group. Tibaldi C, et al. Among authors: russo f. Lung Cancer. 2005 Apr;48(1):121-7. doi: 10.1016/j.lungcan.2004.10.008. Epub 2004 Dec 10. Lung Cancer. 2005. PMID: 15777979 Clinical Trial.
Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer.
Novello S, Falcone A, Crinò L, Rinaldi M, Nardi M, De Marinis F, Tonato M, Tibaldi C, Tinazzi A, Russo F, Grassivaro N, Scagliotti GV. Novello S, et al. Among authors: russo f. Lung Cancer. 2009 Dec;66(3):327-32. doi: 10.1016/j.lungcan.2009.02.009. Epub 2009 Mar 28. Lung Cancer. 2009. PMID: 19329221 Clinical Trial.
Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial.
Gridelli C, Kaukel E, Gregorc V, Migliorino MR, Müller TR, Manegold C, Favaretto A, Martoni A, Caffo O, Schmittel A, Rossi A, Russo F, Peterson P, Muñoz M, Reck M. Gridelli C, et al. Among authors: russo f. J Thorac Oncol. 2007 Mar;2(3):221-9. doi: 10.1097/JTO.0b013e318031cd62. J Thorac Oncol. 2007. PMID: 17410045 Free article. Clinical Trial.
Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study.
Urba S, van Herpen CM, Sahoo TP, Shin DM, Licitra L, Mezei K, Reuter C, Hitt R, Russo F, Chang SC, Hossain AM, Frimodt-Moller B, Koustenis A, Hong RL. Urba S, et al. Among authors: russo f. Cancer. 2012 Oct 1;118(19):4694-705. doi: 10.1002/cncr.27449. Epub 2012 Mar 20. Cancer. 2012. PMID: 22434360 Free article. Clinical Trial.
Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer.
Paz-Ares LG, Altug S, Vaury AT, Jaime JC, Russo F, Visseren-Grul C. Paz-Ares LG, et al. Among authors: russo f. BMC Cancer. 2010 Mar 8;10:85. doi: 10.1186/1471-2407-10-85. BMC Cancer. 2010. PMID: 20211022 Free PMC article. Clinical Trial.
1,883 results